Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

A, Lipton; RL, Theriault; GN, Hortobagyi; J, Simeone; RD, Knight; K, Mellars; DJ, Reitsma; M, Heffernan; JJ, Seaman

doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z

Public

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

Shared by NobleBlocks on Mar 1, 2000 • 12:00 AM UTC

Authors:

Lipton A

Theriault RL

Hortobagyi GN

Abstract

Background Pamidronate therapy previously has been shown to reduce skeletal complications effectively for up to 12 months in breast carcinoma patients with bone metastases. The current study data provide further follow-up results regarding the effects of long term (up to 24 months) pamidronate treat...

Discussions